Monobenzone is the topical agent used for this purpose.
Dermatitis produced by applications of monobenzone in patients with active vitiligo.
Corneal and conjunctival effects of monobenzone in patients with vitiligo.
Corticosteroid Systemic: Adrenal suppression Topical: atrophy, striae, acne Minigrafting Infection, cobble stoning, pitted scars (donor site) Split skin grafting Infection, epidermal cysts, atrophy (donor site) Monobenzone
According to the potent melanoma immunotherapy theory using monobenzone [54, 55, 57-59], tyrosinase appears to trigger melanoma regression.
D'Ischia, "A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity," Chemical Research in Toxicology, vol.
Lerner, "Dermatitis produced by applications of monobenzone in patients with active vitiligo," Archives of Dermatology, vol.
van Swieten et al., "Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy," Journal of Investigative Dermatology, vol.